辛伐他汀联合氯沙坦及褔辛普利治疗慢性肾病的疗效  

Effects of simvastatin combinate with losartan and fosinopril in the treatment of chronic kidney

作　　者：马达[1] 严金龙[1] 高继玲[1] 

机构地区：[1]新疆医科大学第二附属医院肾病科,乌鲁木齐830002

出　　处：《中国临床药理学杂志》2011年第8期577-579,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察辛伐他汀与氯沙坦及福辛普利联合治疗慢性肾病的疗效。方法选择本院住院的非糖尿病肾病患者62例,随机分为2组(均n=31)。在严格执行饮食治疗及降压治疗的基础上,治疗组用辛伐他汀20 mg.d-1、氯沙坦50 mg.d-1、褔辛普利10 mg.d-1口服治疗;对照组用氯沙坦50 mg.d-1和褔辛普利10 mg.d-1口服治疗。2组均疗程1年。结果治疗组24 h尿蛋白定量明显低于对照组(P<0.05)。结论氯沙坦、福辛普利联合他汀类调脂药治疗非糖尿病肾病,可能较传统的氯沙坦联合福辛普利治疗能更为有效地减少尿蛋白,延缓肾脏病的进展速度。Objective To explore the therapeutic effects of combination of simvastin,losartan and fosinopril in the treatment of chrinic kidney disease（CKD）.Methods Sixty-two patients with CKD were randomly divided into two groups,both two groups received conventional therapy then the control group received 50 mg·d-1 of losartan（ACEI）,10 mg·d-1 of fosinopril（ARB）,while the treated group was added orally 20 mg of simvastatin every night.The blood glucose,blood pressure,Upr and Scr in the patients of two groups were compared before treatment and 3,6 months after treatment.Results The urinary protein level decreased significantly in treated group（P0.05） but unchanged in control group.Conclusion ACEI and ARB combinating with simvastatin may show more protective effects on patients with chronic kidney disease.

关 键 词：辛伐他汀 氯沙坦 褔辛普利 蛋白尿 

分 类 号：R692.3[医药卫生—泌尿科学] R972.6[医药卫生—外科学]